Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04403763 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT04403763: Clinical Trial Phase 1 study, sponsored by AbbVie.
NCT04403763 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04403763, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AGN-241622 ophthalmic solution for the first time in human participants
Primary Outcome
The number of participants who experience one or more TEAE during the treatment period
Interventions
- DRUG Vehicle
- DRUG AGN-241622
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2020-07-27 |
| Est. Completion | 2022-12-05 |
| Phase | Phase 1 |
Why NCT04403763 stopped before completion
NCT04403763 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT04403763 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04403763 about?
NCT04403763 is a clinical study titled "Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia". The objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AGN-241622 ophthalmic solution for the first time in human participants
What is the current status of trial NCT04403763?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2020-07-27. Estimated completion is 2022-12-05.
What interventions are being tested in trial NCT04403763?
The interventions under investigation include: Vehicle (DRUG), AGN-241622 (DRUG).
Who is sponsoring clinical trial NCT04403763?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04403763's enrollment target sits among peer trials
80 672nd of 2000 higher than 1,305 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI